Chemotherapy showed no clear difference in overall survival (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
Chemotherapy showed no clear difference in overall survival (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (low certainty).
Chemotherapy showed no clear difference in progression‐free survival (non‐taxane monotherapy vs taxane… compared with chemotherapy (low certainty).
Chemotherapy showed no clear difference in tumour response rate (non‐taxane monotherapy vs taxane monotherapy) compared with chemotherapy (low certainty).
It is very uncertain whether chemotherapy changes tumour response rate (taxane‐containing doublet therapy vs taxane… compared with chemotherapy (very low certainty).
Usual care may leads to lower relapse at 12, 18 or 24 months compared with immunosuppressive withdrawal after monotherapy (low certainty).
It is very uncertain whether usual care changes new CD‐related complications compared with immunosuppressive withdrawal after monotherapy (very low certainty).
Usual care showed no clear difference in adverse events compared with immunosuppressive withdrawal after monotherapy (low certainty).
It is very uncertain whether usual care changes serious adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).
It is very uncertain whether usual care changes withdrawal due to adverse events compared with immunosuppressive withdrawal after monotherapy (very low certainty).